Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuo Miyoshi

Showing results (161-170 of 178) with videos related to

Pageof 18
Sort By:
Breast Cancer (Tokyo, Japan)|January 14, 2025
Clinical utility of tumor-infiltrating lymphocyte evaluation by two different methods in breast cancer patients treated with neoadjuvant chemotherapyMasayuki Nagahashi, Eri Ishikawa, Takahiro Nagai, et al.
Breast Cancer (Tokyo, Japan)|February 24, 2012
Biological characteristics of luminal subtypes in pre- and postmenopausal estrogen receptor-positive and HER2-negative breast cancersKeiko Murase, Ayako Yanai, Masaru Saito, et al.
Cancer Science|January 15, 2026
Pembrolizumab for Early-Stage Triple-Negative Breast Cancer: KEYNOTE-522 Japan Subgroup AnalysisMasato Takahashi, Hirofumi Mukai, Toshimi Takano, et al.
Breast Cancer (Tokyo, Japan)|August 7, 2009
Predictive factors for anthracycline-based chemotherapy for human breast cancerYasuo Miyoshi, Masafumi Kurosumi, Junichi Kurebayashi, et al.
Breast Cancer Research and Treatment|June 26, 2024
Prognostic value of the 21-Gene Breast Recurrence Score® assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial)Takayuki Iwamoto, Naoki Niikura, Kenichi Watanabe, et al.
The Lancet. Oncology|May 2, 2024
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trialTanja Fehm, Francesco Cottone, Kyle Dunton, et al.
Breast Cancer (Tokyo, Japan)|April 2, 2021
Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapyKenichi Inoue, Norikazu Masuda, Hiroji Iwata, et al.
Cancer Science|July 5, 2003
Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancerYusuke Oji, Yasuo Miyoshi, Satoko Koga, et al.
The Journal of Clinical Investigation|November 13, 2018
Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancerYoshikazu Johmura, Ichiro Maeda, Narumi Suzuki, et al.
Oncotarget|February 1, 2020
Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancerYoshimasa Miyagawa, Ayako Yanai, Takehiro Yanagawa, et al.
Pageof 18

Showing results (161-170 of 178) with videos related to

Sort By:
Pageof 18
Breast Cancer (Tokyo, Japan)|January 14, 2025
Clinical utility of tumor-infiltrating lymphocyte evaluation by two different methods in breast cancer patients treated with neoadjuvant chemotherapyMasayuki Nagahashi, Eri Ishikawa, Takahiro Nagai, et al.
Breast Cancer (Tokyo, Japan)|February 24, 2012
Biological characteristics of luminal subtypes in pre- and postmenopausal estrogen receptor-positive and HER2-negative breast cancersKeiko Murase, Ayako Yanai, Masaru Saito, et al.
Cancer Science|January 15, 2026
Pembrolizumab for Early-Stage Triple-Negative Breast Cancer: KEYNOTE-522 Japan Subgroup AnalysisMasato Takahashi, Hirofumi Mukai, Toshimi Takano, et al.
Breast Cancer (Tokyo, Japan)|August 7, 2009
Predictive factors for anthracycline-based chemotherapy for human breast cancerYasuo Miyoshi, Masafumi Kurosumi, Junichi Kurebayashi, et al.
Breast Cancer Research and Treatment|June 26, 2024
Prognostic value of the 21-Gene Breast Recurrence Score® assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial)Takayuki Iwamoto, Naoki Niikura, Kenichi Watanabe, et al.
The Lancet. Oncology|May 2, 2024
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trialTanja Fehm, Francesco Cottone, Kyle Dunton, et al.
Breast Cancer (Tokyo, Japan)|April 2, 2021
Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapyKenichi Inoue, Norikazu Masuda, Hiroji Iwata, et al.
Cancer Science|July 5, 2003
Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancerYusuke Oji, Yasuo Miyoshi, Satoko Koga, et al.
The Journal of Clinical Investigation|November 13, 2018
Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancerYoshikazu Johmura, Ichiro Maeda, Narumi Suzuki, et al.
Oncotarget|February 1, 2020
Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancerYoshimasa Miyagawa, Ayako Yanai, Takehiro Yanagawa, et al.
Pageof 18